The Wagoner County Sheriff's Office (WCSO) released body cam video of deputies responding to a diabetic driver who went off the roadway and crashed into a tree ...

Between 2019 and 2023, prescriptions for nasal spray formulations increased from 4% to 48%, those for glucagon autoinjectors increased by 18%, and those for unmixed syringes dipped from 96% to 31% ...

According to McCulloch, Xeris is the only glucagon company “out there advocating for the new guidelines and promoting in the space.” Amphastar's intranasal glucagon dry powder, Baqsimi ...

Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Glucagon is a recognised therapy for the disorder ... 2019 as a hypoglycaemia rescue therapy for diabetics. Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar indication.

Intranasal (IN) delivery of medications is ... topical anesthetics, glucagon for hypoglycemia, and agents for epistaxis control. Many new medications, or new uses for common medications via ...